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ABSTRACT
Early Postpartum Hemorrhage (EPH) is one of the leading causes of postpartum mortality. It is defined as blood loss of at 
least 500 mL after vaginal or 1000 mL following cesarean delivery within 24 hours postpartum. The following paper includes 
literature review aimed to estimate the incidence and predictors of early postpartum hemorrhage (EPH). Available prevention 
and treatment methods were also assessed. The inclusion criteria for the study were met by 52 studies. 
The exact frequency of EPH in different populations varies from 1.2% to 12.5%. Maternal, pregnancy-associated, labor-
correlated and sociodemographic risk factors seem to be important predictors of EPH. In these cases appropriate prophylaxis 
should be considered. However, EPH may occur without previous risk factors. The main reason for EPH is uterine atony 
which contributes to up to 80% of cases of postpartum hemorrhage (PPH). Other common reasons for PPH include genital 
tract injuries, placenta accreta or coagulopathies. Interestingly, the majority of uterotonics seem to have a similar effect. 
However, carbetocin seems to be the most effective in certain situations. 
Appropriate diagnosis of EPH is the most important issue. The treatment should be causative. The first-line treatment should 
include uterotonics. Surgical interventions, if required, should be performed without delay, although preoperative uterine 
tamponade should be considered due to its high effectiveness. 
Medical staff training in medical simulation centers is an important factor that improves the outcomes of EPH treatment. 
It provides adaptation to hospital protocols, team work improvement, self-confidence building, more accurate blood loss 
evaluation and reduced perception of stress. The implementation of systematic trainings provides better outcomes in the future. 
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INTRODUCTION
Early postpartum hemorrhage (EPH) is usually defined as 
blood loss of at least 500 mL following vaginal delivery (VD) 
or 1000 mL following a cesarean section (CS) within 24 hours 
postpartum [1–3]. Late postpartum hemorrhage (LPH) oc-
curs after 24 hours following labor and complicates 0.23% 
of deliveries. According to the American College of Obste-
tricians and Gynecologists, EPH may be recognized with 
the presence of signs of hypovolemia within 24 hours after 
delivery [4]. EPH may be divided into minor (500–1000 mL), 
moderate (1001–2000 mL) and severe (> 2000 mL) [3]. 
This complication significantly impacts global women’s 
health as the most frequent reason for perinatal deaths all 
over the world [2].
The volume of blood loss is usually estimated visually. 
However, this method is connected with a high possibility 
of error. The underestimation occurs in 30 to 50% if it is 
only visual [1]. To make the assessment more objective it is 
highly advisable to count utilized medical materials, such as 
surgical towels and drapes. Estimating weight difference of 
dry unused materials and those soaked with blood seems 
to be another effective method. Using a calibrated collector 
bag is also recommended for a more accurate blood loss 
estimation. Gravimetric blood loss measurement includes 
weighing bags after delivery [5]. Modified Brecher`s formula 
consists in hemoglobin measurement after delivery which 
makes the evaluation more accurate.
Undiagnosed abnormal postpartum blood loss (UP-
PBL) is defined as decrease in hemoglobin level of at least 
2 g/dL without any symptoms or signs of EPH [6]. Apart from 
an increased risk of maternal mortality (12 to 17.2%) EPH 
may lead to further serious complications related to severe 
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anemia, such as acute kidney injury (29.3%), hepatic failure, 
Sheehan Syndrome, adult respiratory distress syndrome 
(24.6%) and disseminated intravascular coagulopathy (DIC) 
(11.7%) [2]. 
The following paper includes a literature review of 
recent studies regarding PPH. The main aim of the study 
was to estimate the incidence and predictors of EPH. Available 
prevention and treatment methods of EPH were also assessed.
MATERIAL AND METHODS
The authors searched PubMed database for articles 
concerning postpartum hemorrhage published from June 
2014 to April 2019. Searching with ‘postpartum hemorrhage’ 
query revealed 186 original studies. The inclusion criteria 
for the study were: a uniform definition of EPH (blood loss 
of at least 500 mL after VD or 1000 mL following CS within 
24 hours postpartum), a study group ≥ 250 patients and 
the English language of the manuscripts. 52 studies met 
the inclusion criteria (Fig. 1).
RESULTS
According to the WHO postpartum hemorrhage is one 
of the leading reasons for postpartum mortality, especially 
in developing countries of Asia (30.8%) and Africa (33.9%). 
Conversely, in developed countries the average mortality 
rate was estimated to 13.4% of all PPHs (1.2–49.6%). The 
exact frequency of EPH in different populations is shown 
in Table 1 [6–10] and varies from 0.4% to 33%.
Etiology
The leading cause of EPH is uterine atony which con-
tributes 60 to 80% of those complications and 20–30% 
of mothers’ deaths [10]. Childbirth via CS may also lead 
to PPH. There are only few papers concerning PPH occur-
rence after CS in which PPH ratio amounted to 0.3–6% [11]. 
The prevalence of PPH has increased over the past few 
years, which may be caused by an increased incidence of 
uterine atony and CS. The number of emergency hyster-
ectomies (5.8–6.3/10,000 births), blood transfusions, per-
forming B-Lynch sutures (10.7/10,000 births) and uterine 
artery embolizations are the most correlated with uterine 
atony. Other common causes of EPH are genital tract injuries 
or episiotomy (16.7%), placental abnormalities (4 to 36% 
of retained placenta, abnormal placental implantation or 
placental abruption) or coagulopathies (e.g. anticoagulant 
treatment or DIC) (7.4%) [10].
Risk factors 
Unmodifiable risk factors of EPH include a history of EPH 
(OR = 2.3–10.5) and a delivery of a large for gestational age 
Figure 1. Study flow diagram
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fetus (> 4000 g) (OR = 1.7–1.9). Uterine abnormalities such 
as uterine fibroids (OR = 2.0–2.7) also played an important 
role in the incidence of EPH [6]. Pregnancy complications, 
such as maternal anemia (hemoglobin level below 9 [g/dL]) 
(OR = 4.1), hypertensive disorders (OR = 1.6–3.6), gesta-
tional diabetes mellitus (OR = 1.6), a multiple gestation 
(OR = 1.5–3.7), polyhydramnios (OR = 2.6) and preterm de-
livery (OR = 2.6) were significantly correlated with EPH [12]. 
Maternal fever (OR = 1.7–2.5), labor induction (OR = 1.5–1.7) 
and instrumental (OR = 1.2–2.9) or operative delivery 
(OR = 1.4–5.7) increase the risk of EPH. Retained placenta 
increase the risk of hemorrhage immediately after delivery 
(OR = 3.5–4.1) as well as after subsequent pregnancy [12].
Sociodemographic factors, such as obesity 
[BMI > 35 (kg/m2)] (OR = 2.3), mother’s age over 35 years 
(OR = 1.5–1.7) and Middle Eastern ethnicity (OR = 1.8) increase 
the risk of EPH [13]. Conversely, smoking (OR = 0.8) during 
pregnancy seems to reduce the risk of EPH [6, 13]. All the 
mentioned risk factors of PPH are shown in Table 2 [6, 10, 14].
Risk factors of UPPBL are similar to those in EPH and 
include Asian ethnicity (aOR = 2.3), previous cesarean section 
(aOR = 3.4), episiotomy (aOR = 2.6), primiparity, prolonged 
labor, instrumental delivery and retained placenta [6].
Prevention
WHO guidelines for the prevention of EPH include a thor-
ough assessment of possible risk factors as the primary pro-
phylaxis of this complication. Moreover, pharmacological 
prophylaxis includes 10 IU of oxytocin in bolus (intravenously 
or intramuscularly), 100 µg of carbetocin (intravenously or 
intramuscularly), misoprostol (400 µg or 600 µg, per os), er-
gometrine/methylergometrine (200 µg, intramuscularly 
or intravenously) or oxytocin and ergometrine together 
(5 IU and 500 µg, intramuscularly) [15]. According to Ger-
man guidelines 3–5 IU of intravenous oxytocin or 100 µg of 
intravenous carbetocin should be recommended (Tab. 3.) [1]. 
Conversely, RCOG suggested 0.5–1 g of intravenous injection 
of tranexamic acid, carboprost or misoprostol to be superior 
to oxytocin prophylaxis. However oxytocin and/or ergomet-
rine or 100 μg of intravenous carbetocin is highly advised, 
similarly to the guidelines of the Society of Obstetricians and 
Gynaecologists of Canada [3]. RCOG guidelines suggest that 
the prevention of minor EPH with 5 IU and 10 IU of oxytocin has 
comparable results [3]. ACOG recommends to prevent EPH by 
using 10 IU of oxytocin intramuscularly or intravenously as the 
most effective [4]. An intravenous bolus of tranexamic acid at 
a dose of 0.5–2 g (15–30 mg/kg BW) should also be considered 
[2, 3]. Moreover, it could be used as prophylaxis of EPH after VD.
In twin pregnancies carbetocin prophylaxis of EPH after 
CS seems to be more effective than oxytocin in the prevention 
of EPH [16]. The authors found several publications concern-
ing a higher efficacy of carbetocin than oxytocin in the 3rd 
stage of labor. Moreover, in another study carbetocin was 
a better alternative to traditional oxytocin in the prevention of 
PPH after vaginal delivery. The most significant adverse effect 
after drug administration was hypotension with no difference 
between those two drugs. Pruritus was the only symptom 
which was more often experienced in carbetocin-treated 
group. By contrast, the authors of another study reported 
that carbetocin had the same effectiveness as oxytocin at 
lower doses and needed less time to be effective. Conversely, 
misoprostol needed the longest period to reach sufficient 
uterine contractility [17]. No differences in effectiveness were 
Table 1. Frequency of PPH [3, 10, 13, 15, 17–35] identified using 
a multivariable analysis, were: retained placenta (OR 3.5, 95% CI 
2.1–5.8
Country Years Population PPH frequency
Israel 1988–2002 154 311 0.4%
Africa
Asia
Europe
2008 505 379
Severe EPH: 
0.3–3.8%
2.7%
5.5%
Asia, Africa, 
Middle East, 
Latin America 
(data from 
28 countries) 
2010–2011 274 985 VD: 1.2%
WHO 2012 2%
USA  1995–2004 870 000 2.93%
USA 1999–2008 8 500 000 3%
USA 2006–2012 1 339 397 CS: 2%
Canada 2003–2010 2 200 000 6.2%
Norway 1999–2004 307 415 Severe EPH: 1.1%
Norway 2008–2011 43 105 Severe EPH: 2.5%
United Kingdom 2003–2013 24 230 CS: 12.4%
France 2004–2006 146 781 6.4% 
France 2016 3 917 VD UPPBL: 11%VD EPH: 11.2%
Nederland 2000–2008 1 599 867 4.5%
Denmark 2008 147 132 CS: 2.24%VD: 1.75%
Ireland 1999–2009 649 019 2.6% 
Spain 2017 1 352 691 3%
Brazil 2010 9 555 12.5%
RPA 2012 15 725 2.5%
Nigeria 2014 4 889 3.4%
India 2010–2012 96
CS: 1.8% 
VD: 1.3%
Instrumental: 5.3%
Tunisia 2010–2013 39
Severe PPH 
included 
to the study
Japan 2011 1 294 VD: 33%
German 2010–2013 1 550 8.4%
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reported for an intravenous administration of 100 μg of car-
betocin and 5 IU of oxytocin [18]. Furthermore, no differences 
in efficacy were found between 10 IU and 30 IU of oxytocin 
administered intravenously, but the higher dose was effective 
for a longer period (8–12 vs 2–4 hours) [19]. 
The authors found the advantages of 5 IU of oxytocin 
administered intramuscularly over 200 μg of sublingual 
misoprostol. However, misoprostol is more cost-effective, 
may be stored at room temperature and is easier to use. 
Therefore, it may be a good alternative to oxytocin. Heat- 
stable carbetocin compared to oxytocin and 800 μg of 
rectal misoprostol had a similar effectiveness compared 
to 10 IU of intramuscular oxytocin in the 3rd stage of 
labor [20]. 
Several studies compared the effectiveness of 10 IU of 
bolus of oxytocin with 600 µg of intramuscular misoprostol 
in the prevention of EPH, with no significant differences 
between groups. Furthermore, other authors found that 
800 µg of misoprostol seemed to be more effective than the 
standard dose of oxytocin [21]. 
A combination of methylergonovine and oxytocin 
infusion during CS successfully decreased severity of EPH [22]. 
On the other hand a combination of misoprostol and 
oxytocin seemed to increase the risk of side effects related 
to pharmacotherapy, such as fever, nausea and shivering.
Tranexamic acid was effective in reducing the rate of 
EPH, especially if administered within 3 hours after labor 
(RR 0.69, 95% CI: 0.5–0.9; p = 0.008) [23]. Another study 
demonstrated that tranexamic acid did not enhance the 
anti-hemorrhagic effect in a group of women after oxytocin 
administration [24]. The supplementation of fibrinogen after 
EPH in women with normal fibrinogen level also did not 
improve those results. In contrast to those findings some 
researchers recommended a routine administration of 3 g 
of fibrinogen in case of EPH. 
Delayed umbilical cord clamping and cord drainage 
presented a protective effect against EPH. 
Table 3. Carbetocin usage
Multiple pregnancy
≥ 4 deliveries in past
≥ 2 cesarean sections in past
Other uterine scare
Large uterine fibroids
PPH or uterine atony in the past
Suspected fetal macrosomia 
Polyhydroamnios
Placenta previa
Placenta accreta
BMI > 35 kg/m2
HCT < 35%
Fibrinogen concentration < 4 g/L
PLT < 100 000
BMI – body mass index; HCT – hematocrit; PLT – platelets
Table 2. Risk factors of PPH [10, 15, 17, 21, 22, 25, 27, 30, 36, 41–44] 
the incidence of severe postpartum hemorrhage (PPH
Risk factors of PPH
OR 95% CIMother diseases and pregnancy-
associated conditions 
Past history of PPH 2.3–10.5 1.3–10.6
Uterine anomaly in the past 2.4 1.2–5.0
Uterine surgery in the past 3.4 1.6–7.1
Multiple pregnancy 1.5–3.7 1.3–5.3
IVF/ICSI 1.8–2.9 2.2–3.9
Preeclampsia or HELLP syndrome 1.8–3.6 1.6–5.7
Hypertension disorder 1.6–2.0 1.1–3.9
Chorioamnionitis 2.9 2.5–3.4
Delivery < 37 weeks of gestation 2.6 2.3–3.0
Delivery > 41 weeks of gestation 1.6–1.9 1.0–2.8
Fibroids 2.0–2.7 1.8–4.2
Lacerations 2.4 2.0–2.8
Nulliparity 1.1–2.0 1.0–2.6
Third pregnancy 1.3 1.1–1.6
Anemia (Hb ≤ 9.0 g/dL) 4.1 2.8–6.1
GDM 1.6 1.1–2.3
Polyhydramnios 2.6 1.2–5.5
Anticoagulant medication 4.7 2.8–7.7
Placenta previa 3.0–7.0 2.9–7.3
Labour related factors
Retained placenta 3.5–4.1 2.1–5.8
Placenta accrete 3.3 1.7–6.4
Instrumental delivery 1.2–2.9 0.9–3.5
CS 1.4–5.7 1.2–6.5
CS in the second stage of labor 2.1–3.4 1.2–4.7
Uterine rupture 11.6 9.7–13.8
Labour Induction 1.5–1.7 1.1–2.0
PROM 1.4–1.5 1.0–1.9
Body temperature in labour > 38°C 1.7–2.5 1.1–3.6
Labour induction or augmentation 1.4–2.0 1.1–2.4
LGA 1.7–1.9 1.2–2.6
Sociodemographic
BMI > 35kg/m2 2.3 1.3–3.6
Age > 35 years 1.5–5.7 1.1–7.1
Middle Eastern descent 1.8 1.2–2.7
African descent 1.5 1.1–2.2
Smoking 0.8 0.6–1.0
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Treatment
It is important to estimate the occurrence of probable 
reversible reasons for EPH. An injury of the uterus or the 
genital tract seems to be the most recognizable factor and 
requires primary surgical treatment. 
The management of retained placenta includes 
controlled cord traction, Credé maneuver and manual 
placenta removal [2].
External uterine massage or bimanual uterine com-
pression should be considered as the first-line treatment 
of uterine atony. The second-line treatment might involve 
intrauterine tamponade with Foley catheter, or other dedi-
cated intrauterine balloon catheters, which effectiveness 
reached up to 80–90% [25]. The availability, easy usage and 
safety are important issues of this method when uterine 
subatony or undiagnosed focal placenta accreta is present. 
However, no papers have been found to compare those 
methods. Early balloon tamponade is effective when used 
before coagulopathy occurrence. 
Another tools utilized in the treatment of uterine suba-
tony are uterine compression sutures (B-Lynch, Cho and 
Hayman) with effectiveness estimated to 60–75% [26]. 
However there is insufficient data concerning com-
parison of different techniques. On the other hand 
endovascular balloon techniques seem to be more ef-
fective (uterine preservation, less blood loss and higher 
postoperative hemoglobin levels). Several previous stud-
ies showed similar effectiveness of compression sutures, 
intrauterine tamponade and uterine artery ligation. How-
ever, intrauterine tamponade should be preferred option 
because of lower costs and invasiveness as well as faster 
therapeutic effect. In severe cases combination of afore-
mentioned methods should be considered to preserve 
female fertility [26].
Obviously, pharmacologic treatment should be intro-
duced simultaneously — intravenous 10–30 IU of oxytocin 
or 100 µg of intravenous bolus of carbetocin, with similar 
clinical effectiveness (blood loss, severe postpartum hemor-
rhage, blood products transfusions). On the other hand few 
studies has shown higher effectiveness (amount of blood 
loss and the need for other uterotonics) of 100 µg carbetocin 
vs 5 IU oxytocin in EPH management [17].
Other vasoconstrictors, such as methylergometrine 
0.2–0.4 mg intramuscularly, PGF2α (enzaprost) 1 mg into 
the uterine muscle, PGE1 (misoprostol) 600–1000 µg per 
rectum are also used [2].
Total hysterectomy is the last-ditch intervention in 
case of uterine atony. The incidence of such intervention 
constitutes 1.1–2.3% of EPH [27] and 0.63 per 1000 child-
births. Over 30 minutes desmopressin infusion 0.3 µg/kg 
BW should be considered in women with hypovolemic 
shock [28].
The administration of crystalloids and colloids should 
be obligatory apart from drugs increasing the contractility 
of the uterus. In case of massive perinatal bleeding, blood 
product transfusion (4 or more units of packed red blood 
cells (RBC), fresh frozen plasma (12–15 mL/kg BW), (25 IU/kg 
BW) prothrombin complex concentrate and platelets, when 
platelet count is below 75*109/l) should be considered [2, 3]. 
One study suggested cell salvage but this procedure is very 
expensive and not easily available.
1 g of calcium chlorate and the substitution of fibrinogen 
(30–60 mg/kg BW), rFVIIa (90 µg/kg BW or 15–20 IU/kg BW) 
or factor XIII should be considered when severe bleeding 
is present [3]. 
Late EPH requires vaginal microbiology and subsequent 
antimicrobial treatment of endometritis if such a diagnosis 
is confirmed. Ultrasound should be performed to look 
for placenta retained tissue and subsequent surgical 
intervention should be planned. 
Medical simulations of EPH are important for the 
improvement of medical staff skills. A reduction in the number 
of possible errors, easier and faster medical interventions, 
shortening the time to the preparation of blood products, 
more appropriate blood loss evaluation, self-confidence 
and comfort level, practices in surgical and pharmacological 
management are the main goals of medical simulations 
[29]. Such courses improve the recognition of EPH and 
shorten the duration of appropriate medical intervention 
— uterine massage and the administration of second-line 
medications. The results showed an improvement of medical 
skills in that publication from 27.3% to 63.6% (p = 0.01) 
[30]. Another study showed a significant improvement in 
team cooperation [31]. Some research also showed that 
such simulations have a positive influence on obstetric 
outcomes in the future. A subsequent trial showed a higher 
rate of appropriate EPH evaluation and fundal massage 
implementation. Another publication proved that one-day 
simulation caused a significant improvement in medical 
skills and the effect persisted over the next 3 months (0.4% 
vs 0.03%, OR 19, 95% CI 2.5–147) [32]. 
DISCUSSION
An inconsisenst definition of EPH, varying across coun-
tries contributes to the publication of non-comparable 
results and different conclusions concerning EPH. The fre-
quency of EPH was compared in this study and an increasing 
trend was observed. Furthermore, EPH is the main cause of 
maternal mortality [32]. Apart from death it is associated 
with severe maternal condition after childbirth. Therefore, 
an interest in the subject is not surprising. Risk factors listed 
in the Results section are one of research areas. Prediction 
strategy assumes risk factor evaluation before any childbirth. 
EPH causes may be easier to memorize by remembering 
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their division in 4Ts: tone, tissue, trauma and thrombin with 
higher attention to uterine atony as the most frequent cause 
of EPH [10]. It seems that an increased rate of EPH is caused 
by an increased level of uterine atony secondary to a higher 
rate of CSs. Regrettably, EPH occurs in two-thirds of women 
without any risk factors [28].
It is commonly known that it is better to prevent than to 
treat possible complications. For that reason, the main atten-
tion is paid to preventive methods which consist of utero-
tonics (oxytocin, carbetocin, enzaprost/carboprost or miso-
prostol, ergometrine or methylergometrine) and tranexamic 
acid. Thus, the prophylaxis should include 3–10 IU of oxyto-
cin intravenously or 100 µg of carbetocin intravenously in 
the 3rd stage of labor and 100 µg of carbetocin intravenously 
during CS in high risk patients. Economic issues should also 
be considered because of a higher carbetocin cost. More-
over, an intravenous administration of oxytocin was shown 
as more effective (due to severe EPH, blood transfusion and 
admission to a high dependency unit) than intramuscular 
administration in the 3rd stage of labor [33]. Another trial 
showed acceptable outcomes of misoprostol in comparison 
with oxytocin, but a high price of misoprostol was em-
phasized [34]. Previous studies showed also the efficacy of 
other uterotonics in the absence of oxytocin and carbetocin. 
Tranexamic acid should be also considered.
Apart from early prophylaxis, in any case of EPH  phar-
malological and if severe - surgical treatment should be in-
troduced. Pharmacologic intervention seems to be superior 
to a surgical one. However, if surgical intervention is neces-
sary, no delay in its performance should occur, especially 
when regards pelvic vessel occlusion, compression sutures 
(eg B-Lynch) management or emergency hysterectomy. 
Hamilton maneuver is the best option in preparation to the 
surgical procedures.
In case of hypovolemic shock, desmopressin 0.3 µg/kg of 
BW and other vasoconstrictors like norepinephrine should 
be considered.
Pelvic packing may be performed in case of the lack 
of selective arterial embolization, for patient transport to 
a tertiary care unit or in case of persistent bleeding after 
hysterectomy [7].
Intravenous infusions of crystalloids and colloids 
should be obligatory apart from previously mentioned 
drugs. Moreover, blood transfusion may be necessary 
[2, 3]. Fibrinogen substitution (30–60 mg/kg BW), which 
could reach ≥ 2 g/L as well as rFVIIa (90 µg/kg BW or 
15–20 IU/kg BW) or factor XIII use could improve the 
PPH outcomes [3].
Medical simulations of EPH are important for the im-
provement of medical staff skills, which had an influence 
on EPH outcomes. Importantly, attention should be paid 
to becoming familiar with hospital protocols, team work 
improvement, understanding one’s own mistakes, building 
self-confidence, and reduced perception of stress. Blood loss 
evaluation is also improved after such trainings. It seems 
rational that it should be implemented as early as the be-
ginning of medical practice and repeated every 3 months. 
No research on the frequency of EPH in the Polish 
population is currently available. Further studies should also 
evaluate more accurate blood loss measurement methods 
and their customization. 
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